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Abstract
The European Prospective Investigation into Cancer and nutrition (EPIC) is a long-term, multi-centric prospective study in
Europe investigating the relationships between cancer and nutrition. This study has served as a basis for a number of
Genome-Wide Association Studies (GWAS) and other types of genetic analyses. Over a period of 5 years, 52,256 EPIC DNA
samples have been extracted using an automated DNA extraction platform. Here we have evaluated the pre-analytical
factors affecting DNA yield, including anthropometric, epidemiological and technical factors such as center of subject
recruitment, age, gender, body-mass index, disease case or control status, tobacco consumption, number of aliquots of
buffy coat used for DNA extraction, extraction machine or procedure, DNA quantification method, degree of haemolysis and
variations in the timing of sample processing. We show that the largest significant variations in DNA yield were observed
with degree of haemolysis and with center of subject recruitment. Age, gender, body-mass index, cancer case or control
status and tobacco consumption also significantly impacted DNA yield. Feedback from laboratories which have analyzed
DNA with different SNP genotyping technologies demonstrate that the vast majority of samples (approximately 88%)
performed adequately in different types of assays. To our knowledge this study is the largest to date to evaluate the sources
of pre-analytical variations in DNA extracted from peripheral leucocytes. The results provide a strong evidence-based
rationale for standardized recommendations on blood collection and processing protocols for large-scale genetic studies.
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Introduction
In recent years, the use of automated methods for DNA
extraction from venous blood samples has generated large
amounts of material for the mapping of genetic variations that
underlie susceptibility to common human diseases [1,2]. DNA is
an abundant molecule in blood (20–60 mg/ml) and is extremely
stable after purification. Since most genome-wide analysis methods
require#1 mg of DNA and for a single SNP assay#10ng of DNA,
this molecule is rarely in short supply when using blood samples
obtained through conventional venipuncture [3]. However in
long-term epidemiological studies such as cohort studies, it is
essential to maximize the yield and quality of DNA in order to
maintain a DNA resource that will last for future research
extending over many years. Thus far, there have been only few
studies addressing pre-analytical variations affecting the yield of
DNA extracted from peripheral blood leucocytes [4].
The European Prospective Investigation into Cancer (EPIC) is a
long-term, multi-centric prospective cohort study with a focus on
nutrition, investigating the etiology of cancers at various sites as
well as other forms of chronic diseases in relation to diet and
lifestyle [5]. The study takes advantage of the contrast in cancer
rates and dietary habits between centers and countries and of its
large overall size, which makes it possible to explore interactions
between nutritional, genetic, hormonal and lifestyle factors [6,7].
The prospective cohort approach includes the collection of
baseline questionnaire and interview data on dietary and non-
dietary variables, as well as anthropometric measurements and
blood samples for long-term storage from apparently healthy
populations. The enrollment of subjects in all EPIC centers took
place between 1992 and 2000. The cohort participants are
followed up over time for the occurrence of cancer and other
diseases, as well as for overall mortality, to allow incidence and
mortality comparisons by exposure variables. At regular intervals,
follow-up questionnaires are used to update information on
selected aspects of lifestyle that are known or strongly suspected
to be related to cancer risk. To date, EPIC has recruited 521,448
participants, in 23 centers located in 10 European countries. The
study started in 1992 with 17 research centers in seven core EPIC
countries (France, Germany, Greece, Italy, The Netherlands,
Spain and the UK). Subsequently, these were joined by centers in
three Scandinavian countries (Sweden, Denmark and Norway)
and one center in Italy (Naples) that were conducting broadly
similar prospective studies. The most recent follow-up period for
cancer incidence was performed between 2004 and 2010, and has
identified 50,336 subjects who developed cancer after cohort
enrollment (incident cases). These cancers cover a very wide range
of anatomic sites and morphologies.
Of the total number of cohort participants, 388,527 have
provided a venous blood sample (30 ml) obtained according to
standard protocols, which was fractionated into plasma, white
blood cells (buffy coat), serum and red blood cells. Except for
samples collected in Sweden and Denmark (which were stored
locally), aliquots corresponding to 15 ml of fractionated blood
were snap-frozen and shipped to a central biobank hosted by the
International Agency for Research on Cancer (IARC, Lyon,
France). These samples are cryopreserved into liquid nitrogen
(2196uC) in plastic straws (CryobiosystemH).
Here, we have assessed the yield of DNA extracted from
approximately 50,000 individual samples collected from individ-
uals in the European Prospective Investigation into Cancer over a
period of 5 years, and we have examined the impact of a range of
pre-analytical variables on the amount of DNA generated using an
automated DNA extraction system.
Materials and Methods
Ethics Statement
The DNA extraction data used in the present study relates to
projects that have been formally endorsed by the EPIC Steering
Committee and approved by the Ethical Review boards of each
participating center and of the International Agency for Research
on Cancer.
Subjects
EPIC was constructed by the integration of different cohorts
into a common framework. In the majority of study centers,
subjects were invited from the general adult population residing in
a given town or geographical area. Exceptions to this recruitment
scheme were the French cohort (based on members of the health
insurance for teacher’s education system), parts of the Italian and
Spanish cohorts (based on members of blood donor associations)
and the cohorts in Utrecht (The Netherlands) and Florence (Italy)
(women invited for a population-based breast cancer screening
program). In Oxford (UK) half of the cohort was recruited among
vegans (who consume no animal products), lacto-ovo vegetarians
and fish eaters (i.e. consumers of fish but not meat). In France,
Norway, Utrecht (The Netherlands) and Naples (Italy) only
women were recruited. Individuals who agreed to participate
signed an informed consent, were mailed a questionnaire on diet
and a questionnaire on lifestyle and were subsequently invited to a
study center for blood donation, anthropometry and measurement
of blood pressure. There were, however, deviations from this
general scheme in several centers according to the nature of cohort
[5,8].
Blood Samples
Thirty ml of blood was obtained by venipuncture and processed
according to standard separation protocols. Biological samples
included blood plasma, blood serum, white blood cells (buffy coat)
and red blood cells were collected from 388,527 of the
521,448 EPIC study participants. In the seven initial EPIC
countries and in Naples (Italy), blood fractions were aliquoted
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into 28 plastic straws containing 0.5ml each (twelve plasma with
sodium citrate, eight serum, four erythrocyte, four buffy coat for
DNA). Plastic straws (CryobiosystemH (CBS), Paris, France), made
of chemically inert and biocompatible ionomeric resin, were
designed for long-term storage. To ensure a high degree of
standardization, the same materials (syringes, straws, etc.) were
purchased centrally and distributed to the centers. The samples
were then split into two mirror halves of 14 aliquots each. One set
was stored locally, and one transported to IARC to be stored in
liquid nitrogen (at 2196uC) in the central biobank.
Separation of Blood Fractions
The 30 ml of blood collected from each participant were
centrifuged while still in the Monovette tube. Centrifugation speed
was set at a value that corresponds to a 15006g centrifugal force.
During centrifugation for at least 20 minutes the samples were
kept at room temperature (620uC). From the Monovette tubes
with anticoagulant, three blood fractions were obtained: plasma,
buffy coat, and red blood cells. Buffy coats (2 ml) were adjusted to
a final volume of 2.5 ml by addition of physiological solution.
From the Monovette without anticoagulant, serum was obtained.
After centrifugation of the three Monovette tubes, four plastic
tubes were prepared, containing: (1) - 4.5 ml serum, (2) - 6.5 ml
plasma, (3) - 2 ml red blood cells +0.5 ml of physiological solution,
(4) - 2 ml buffy coat +0.5 ml of physiological solution. Each plastic
tube was split into plastic straws containing 500 ml of biological
material.
Sample Storage
The central EPIC biobank located at IARC holds 33 Liquid
Nitrogen (LN2) tanks equipped with straw storage systems and
connected to an automated LN2 supply system. The samples are
kept under N2 liquid phase (2196uC). The biobank contains about
3.8 millions straws with blood aliquots from 275,861 EPIC
participants. The straws of each participant are stored together
using the CBSTM visotube/goblet/canister system (Cryobiosys-
temH). Each straw is labeled with the participant’s ID and color-
coded to indicate its contents; in addition, the tube, goblet and
canister are color-coded to aid in identifying the samples. Finally, a
computer software program indicates the container, canister,
goblet, and the location of the goblet and the canister within each
container to track the stored biological samples of each
participant. A Laboratory Information Management System
(LIMS) has been used to identify, track and follow-up during
analysis the different straws contained in each visotube. The
biobank is housed in three purpose-built, ventilated storage rooms.
The pressure in the LN2 tanks is monitored with alarms. The
storage rooms are equipped with LN2 sensors to monitor potential
LN2 health hazards.
DNA Extraction
Genomic DNA from participants was extracted from one or two
aliquots of 0.5 ml aliquot of buffy coat, which had been kept
frozen since blood collection and processing. All DNAs were
extracted at IARC, Lyon, using the Gentra Autopure LS DNA
preparation platform (Qiagen, Hilden, Germany). The two
different automated extractors and the manual technique were
used applying the same DNA extraction protocol. This purifica-
tion protocol included 5 steps:
RBC lysis. There was an incubation of the sample with 15–
19 ml Autopure RBC Lysis solution during 5 min at room
temperature to lyse the red blood cells. The samples were then
centrifuged at 30006g for 2 min to pellet the white blood cells.
Cell lysis and protein precipitation. To disperse the white
blood cell pellet, 1.67 ml Autopure Precipitation Solution were
vigorously dispensed and then 5 ml Autopure Cell Lysis Solution
were added to lyse the white blood cells. The samples were mixed
vigorously to precipitate the proteins and then centrifuged at
30006g for 2 min. Five milliliters of Autopure 100% Isopropanol
were added to the DNA-containing solution.
DNA precipitation. The output tubes were gently rotated 50
times to precipitate the DNA and then the samples were
centrifuged at 30006g for 2 min to pellet the DNA.
DNA wash. A dispense of 5 ml Autopure 70% Ethanol was
done followed by a centrifugation of the samples at 30006g for
1 min to pellet DNA.
DNA hydration. DNA was rehydrated with DNA Hydration
Solution according the required DNA concentration defined by
the users.
DNA Quantification
Two different methods of quantification were used for
measurement of DNA quantity: PicoGreen dsDNA quantitation
assay and NanoDrop ND-8000 8 sample spectrophotometer. The
PicoGreen dsDNA Quantitation Reagent is an ultra-sensitive
fluorescent nucleic acid stain for quantitating double-stranded
DNA (dsDNA). DNA samples were pipetted to 96-well plates for
DNA concentration measurement with PicoGreen dsDNA quan-
titation assay and kit (Molecular Probes, Inc, The Netherlands).
The NanoDrop ND-8000 8 sample spectrophotometer is a full-
spectrum (220–750 nm) instrument that measures 8 individual
1 ml samples.
Statistical Method
To examine those factors that may be related to DNA yield
levels, we modeled DNA yield levels as a linear function of
covariates (generalized linear model with gamma distributed
outcomes and identity link function). For each variable, results
were expressed as regression coefficients reflecting either the
increase (positive value) or the decrease (negative value) in DNA
yield in relation with the variable under consideration. For
categorical variables, coefficients represented the amount of
change in DNA yield in mg as compared to the reference category.
Age, Body Mass Index (BMI) and processing times were treated as
continuous variables. In this case, coefficients represented the
amount of change in DNA yield in mg for one unit change (e.g.
with each year for age, each BMI unit for BMI, and each 30
minutes for processing times). Analyses were adjusted for the
following variables: age, center, gender, BMI, tobacco consump-
tion, number of straws, extraction method and quantification
method. Partial R2 was calculated as the sum of squares of an
independent variable given other independent variables in the
model divided by the residual sum of squares of the model
excluding that independent variable and then multiplying by 100
to get a percentage. Analyses were performed using Stata 11.
Results
Study Design
This study has used data on DNA extraction processed at IARC
and generated in the course of 12 distinct projects developed
between 2006 and 2010 using samples of the EPIC cohort
(Table 1). Of these projects, 10 were focused on specific cancer
cases or etiological risk factors. The two other projects were
focused on diabetes (INTERACT) and on heart diseases (EPIC-
HEART), respectively. The design of each project was a nested
case control study in which ascertained incident cases of disease
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were selected and matched with controls free of the disease of
interest. INTERACT and EPIC-HEART are case-cohort studies,
using incident type 2 diabetes for INTERACT, incident coronary
heart disease and stroke cases for EPIC-HEART, and a joint
referent group which is a random sample of the participants
providing blood samples at baseline.
In each project, samples of buffy coat from cases and controls
were used for DNA extraction using an automated Autopure LS
DNA extraction system (Qiagen, Hilden, Germany). Within the
EPIC study, the samples were from participants recruited in 19
different centres (Table S1). Samples from subjects recruited in
centres from Denmark and Sweden, (which were not stored or
extracted at IARC) were not included in the study.
Data for a total of 52,256 DNA extractions were retrieved in the
laboratory database of the IARC Biological Resource Center
(BRC) and analyzed for variations with respect to a number of
technical, epidemiological or anthropometric factors including
center of subject recruitment, age, gender, body-mass index,
cancer case or control status, tobacco consumption, number of
straws containing buffy coat used for DNA extraction, extraction
machine or procedure (two different Autopure instruments were
used and a small proportion of the samples were extracted
manually), method for DNA quantification (Nanodrop or Pico-
green), degree of haemolysis of the blood sample, and variations in
the timing of pre-analytical sample processing (time between blood
collection by venipuncture and refrigeration at 4uC, time from
refrigeration to centrifugation, time from centrifugation to
Table 1. DNA extraction generated in the course of 12 distinct projects using specimens of the EPIC cohort.
Study
code Study name Objectives
Number
of DNA
extractions
BLAD Participation in GWAS for bladder cancer Nested case control study aimed at identifying novel genetic variants which are worthy of
intensive pursuit in epidemiological, genetic mapping, clinical and laboratory investigations
on bladder cancer.
950
BRCD Participation in the Breast an Prostate Cancer
Cohort Consortium (BPC3) – Breast cancer
component
Nested case-control study aimed at the analysis of genes related to steroid hormone and
insulin-like growth factor-1 metabolism and breast cancer risk in EPIC which is part of the
NCI breast and prostate cancer cohort consortium and GWAS study of ER-negative
breast cancer.
8071
CORD The Influence of Vitamin D and
Polymorphisms of the Vitamin D Receptor
and Calcium Sensing Receptor
on Colorectal Cancer Risk
Nested case-control study aimed at evaluating the roles of both vitamin-D (important in
calcium homeostasis/cell cycle kinetics) and calcium (role in cell cycle kinetics) in
colorectal cancer prevention.
2177
EGAD Genetic susceptibility, environmental factors
and the gastric cancer risk in European
populations (EUR-GAST II)
Nested case-control study aimed at (a) evaluating the effect of dietary and environmental
exposures by histological and anatomical subtypes of gastric cancer; (b) evaluating the
effect of dietary and environmental factors on esophageal adenocarcinomas; (c) evaluating
the main effect of genetic polymorphisms in several candidates genes.
1444
EPHD Study of the interplay of genetic, biochemical
and lifestyle factors in coronary heart disease
(EPIC-HEART)
Nested case-control study aimed at investigating the separate and combined influences
of genetic, biochemical and major lifestyle factors (notably diet) on the incidence of
coronary heart disease (CHD).
7643
HPVD HPV and cervical: the role of diet,
environmental and infectious
cofactors, and genetic susceptibility
Nested case-control study aimed at evaluating the association between serological markers
of HPV infection and cervical cancer as well as the role in cervical carcinogenesis of: (a)
environmental cofactors (diet, tobacco, parity, use of hormonal contraceptives),
(b) infectious cofactors (HSV-2 and C. trachomatis); and (c) markers of genetic
susceptibility.
664
INTD Examination of the interaction of genetic and
lifestyle factors on the incidence of type 2
diabetes (INTERACT)
Nested case-control study aimed at evaluating gene-lifestyle interactions in relation
with type 2 diabetes.
18439
KIDD Genome Wide Association Study of kidney
cancer
The aims of this study are to (i) immediately replicate approximately the top 30 variants in a
large follow-up series, and (ii) substantially replicate between 20,000 and 317,000 variants
following the GWAS of kidney cancer recently completed involving 1400 cases and 2800
controls from an IARC Central Europe study.
792
LUND DNA methylation changes associated with
cancer risk factors and blood levels of
vitamin metabolites
The aim of this study is to investigate the contribution of common human genetic variation
to susceptibility of lung cancer. The association between lung cancer and DNA methylation
patterns in a panel of candidate genes is examined. It is also investigated whether blood
levels of vitamin metabolites modify DNA methylation levels in blood cells. DNA
methylation levels are quantitatively determined in blood cells of nested
cases and controls.
2450
LYMD EPIC Nested case-control investigation on
lymphomas
Nested case-control study aimed at elucidating whether risk factors for lymphoma exert
their effect by modulation of the immune system by studying the inherited and
acquired immune response in non-Hodgkin lymphoma (NHL) cases and controls.
1789
PAND Genome Wide association Study and
pancreatic cancer (PanScan)
Nested case-control study aimed at conducting a whole genome scan (WGS) of common
genetic variants to identify genetic markers of susceptibility to pancreatic cancer.
504
PROD Participation in the Breast an Prostate Cancer
Cohort Consortium (BPC3) – Prostate cancer
component
Nested case-control study aimed at the analysis of genes related to steroid hormone and
insulin-like growth factor-1 metabolism and prostate cancer risk in EPIC which is part of
the NCI breast and prostate cancer cohort consortium and GWAS study of aggressive
prostate cancer.
2238
doi:10.1371/journal.pone.0039821.t001
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Table 2. Technical, epidemiological and anthropometric factors analyzed for evaluation of DNA yield variations.
Variables N %
Gender Men 18680 39.6
Women 28481 60.4
Age ,45 7054 15.0
45–49 6631 14.1
50–54 8835 18.7
55–59 9514 20.1
60–64 8567 18.2
$65 6560 13.9
Body Mass Index Normal (,25) 14449 30.7
Moderate pre-obesity (25–27.5) 12784 27.1
Overweight (27.5–30) 7185 15.2
Moderate obesity (30–35) 8953 19.0
Obesity ($35) 2934 6.2
Missing 856 1.8
Cancer Incidenta 10954 23.2
Non Incident 36207 76.8
Prevalentb 1311 2.8
Non Prevalent 45850 97.2
Time from blood collection to incident cancer diagnosis ,2 years 1813 3.8
2–5 years 3299 7.0
5–10 years 4460 9.5
$10 years 1081 2.3
Missing 36508 77.4
Time from prevalent cancer diagnosis to blood collection ,2 years 240 0.5
2–5 years 298 0.6
5–10 years 340 0.7
$10 years 427 0.9
Missing 45856 97.3
Never 21290 45.1
Tobacco consumption Former 13847 29.4
Current 11067 23.5
Missing 957 2.0
Number of straws 1 11838 25.1
2 35323 74.9
Extraction method Extractor LS1 29441 62.4
Extractor LS2 17305 36.7
Manual 415 0.9
Quantification method Nanodrop 33805 71.7
Picogreen 13356 28.3
Haemolysis Yes 3337 7.1
No 21379 45.3
Missing 22445 47.6
Haemolysis gradient Light haemolysis 2870 6.08
Medium haemolysis 445 0.94
Heavy haemolysis 20 0.05
Missing 43826 92.93
Time from collection to refrigeration ,5 min 2704 5.7
5 min - 1 hour 5421 11.5
1–3 hours 3934 8.3
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cryopreservation at 280uC). In this study we defined cases as
subjects who developed a cancer before or after recruitment,
distinguishing between incident cases, corresponding to subjects
who developed a cancer during the follow-up period, and
prevalent cases, who developed cancer before the recruitment.
The major cancer sites were prostate, breast, lung, bladder, colon,
kidney, cervix and pancreas. Samples with a DNA yield of 0 were
excluded from the statistical analysis (n = 1962). Overall, a total of
47,161 samples were taken into consideration in the final analysis
(Table 2).
Sources of Variations in DNA Yield
The average yield of DNA per extraction, given as total
amount of DNA recovered after extraction, was 68.85 mg
whatever number of straw used (minimum: 1 mg; maximum:
897 mg). When considering DNA extraction from only 1 straw
(0.5 ml of buffy coat), the average yield of DNA was 43.23 mg
compared to 77.43 mg using 2 straws (Table S2). Table 3 shows
the statistical analysis of the effect of anthropometric, epidemi-
ological and technical factors on DNA yield per sample. For
each factor, the analysis was adjusted for main variables listed
in Table 3 (age, gender, BMI, tobacco consumption, number of
straws, extraction and quantification methods) and for center of
blood collection.
DNA yield was significantly associated with the following
individual variables: gender (small but significant increase of
1.44 mg in DNA yield in women), age (overall DNA yield
significantly decreased by about 0.11 mg with each year of age),
BMI (increase of 0.39 mg in DNA yield with each BMI unit),
incident cancer (small but significant increase of 2.49 mg in
DNA yield in subjects who developed a cancer during EPIC
follow-up) and tobacco consumption (DNA yield significantly
increased by 10.87 mg in smokers versus never smokers, non-
significant increase in former smokers). The association with
incident cancer was not attributable to any specific cancer type
or location. In contrast, cancer diagnosis prior to inclusion in
EPIC was not significantly associated with changes in DNA
yield. Among technical variables, significant changes were
observed according to the number of straws used (on average,
extraction with 2 straws generated 30.28 mg of DNA more than
with 1 straw), center (see below), extraction method (there was a
small but significant difference between the two Autopure LS
instruments used, and manual extraction had a significantly
lower yield than either machine). Detection with Picogreen
tended to give higher values than with Nanodrop. This
difference appeared to affect DNA yield mostly for extractions
performed from one straw of buffy coat. When using 2 straws
for extractions, the values obtained with both quantitation
methods were similar (75.41 mg with Picogreen versus 77.65 mg
with Nanodrop). Processing times were also a significant source
of changes. Each 30 minutes of decrease in lag time between
blood taking and refrigeration, and between refrigeration and
centrifugation, resulted in a significant increase in DNA yield of
about 0.23–0.48 mg per sample. In contrast, the time lag
between centrifugation and freezing did not appear to have a
significant impact on the final DNA yield. It should be noted,
however, that about 72% of samples were frozen within a
maximum time of 2 hours after centrifugation.
From a technical viewpoint, the main factor negatively affecting
DNA yield was haemolysis. The lysis of red blood cells was visually
recorded and scored as either ‘‘light’’, ‘‘medium’’, or ‘‘heavy’’.
Presence of haemolysis at any degree was associated with a
reduction of about 8 mg in DNA yield, with an increasing trend
according to the degree of haemolysis. It should be noted,
however, that information on haemolysis was recorded for only
24,716 (52.5%) of the samples.
Variations with Center
Figure 1 shows the variations in the average DNA yield per
sample using 2 straws of buffy coat according to the EPIC centre
of origin of the sample (for variations in samples extracted using
a single straw, see also Table S2). The extent of variation from
one center to the other appeared to be as much as fourfold. The
mean values of lowest yields (for 2 straws) were detected for
center 15 (29.69 mg) and center 14 (40.62 mg) whereas the mean
values of highest yields were for center 16 (112.26 mg) and center
2 (104.27 mg) (Table S2). Table S3 shows the statistical analysis
of the effect of centre of origin on DNA yield. In several of the
Table 2. Cont.
Variables N %
.3 hours 3987 8.5
Missing 31115 66.0
Time from refrigeration to centrifugation ,1.5 hours 498 1.0
1.5–2 hours 3482 7.4
2–6 hours 2153 4.6
$6 hours 1865 4.0
Missing 39163 83.0
Time from centrifugation to freezing ,45 min 6179 13.1
45–59 min 6296 13.4
1–2 hours 6800 14.4
$2 hours 7598 16.1
Missing 20288 43.0
aFirst incident cancer case.
bLast prevalent cancer case.
doi:10.1371/journal.pone.0039821.t002
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centers, there were substantial seasonal variations in DNA yield
according to the date when the blood sample was collected, in
particular in those with the lowest yield (Figure S1). These
seasonal intra-center variations, independently of other process-
ing variables, suggest that in some centers there were significant
differences in the separation, recovery and aliquoting of buffy
coats. Partial R2 analysis identified that the variable ‘‘Center’’
accounted for 16.9% (P,0.0001) of the explained variance,
making it the most important significant predictor for DNA yield.
Qualification for Genotyping Studies
The DNA extracted from EPIC samples has been used in
Genome-Wide Association Studies (GWAS) and candidate gene
studies by different laboratories (Table 1). The methodology used
by laboratories performing GWAS was based either on Illumina or
Sequenom technologies using different types of SNP arrays. Each
laboratory developed its own quality controls procedures,
depending upon the genotyping methodology used. Tables 4
and 5 compile information on samples used in four studies
completed to date and show the percentage of those samples which
Table 3. Effects of individual characteristics and processing variations on DNA yield (mg).
Estimated coefficient
for effect(c) SE P value
Gender
Men reference
Women 1.437 0.388 ,0.01
Age 20.107 0.020 ,0.01
BMI 0.390 0.039 ,0.01
Tobacco consumption
Never smoker reference
Former smoker 0.366 0.375 0.33
Current smoker 10.871 0.515 ,0.01
Incident cancer
No reference
Yes 2.494 0.363 ,0.01
Previous cancer
No reference
Yes 1.252 1.157 0.28
Number of straws used
One straw reference
Two straws 30.276 0.489 ,0.01
Extraction method
Autopure LS 1 reference
Autopure LS 2 22.439 0.434 ,0.01
Manual 26.757 0.994 ,0.01
Quantification method
Nanodrop reference
Picogreen 6.449 0.516 ,0.01
Haemolysis
No reference
Yes 27.895 0.814 ,0.01
Haemolysis
Light haemolysis reference
Medium haemolysis 25.370 1.685 ,0.01
Heavy haemolysis 29.509 9.221 0.30
Time from collection to refrigeration (per 30 minutes) 0.482 0.213 0.02
Time from refrigeration to centrifugation (per 30 minutes) 0.227 0.036 ,0.01
Time from centrifugation to freezing (per 30 minutes) 0.057 0.138 0.68
Time from blood collection to incident cancer diagnosis (per year) 20.138 0.116 0.24
Time from prevalent cancer diagnosis to blood collection (per year) 0.358 0.165 0.03
cThe estimated coefficients for effect reflect the increasing (positive value) or decreasing (negative value) concentration response to the lifestyle/exposure factor,
adjusted for the other lifestyle/exposure factors.
doi:10.1371/journal.pone.0039821.t003
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met qualification criteria as determined by the different labora-
tories to generate exploitable SNP data (DNA amount, concen-
tration). For these analyses, samples with DNA yield = 0 were
retained. Different laboratories have used different criteria
depending on their particular technology setups. Notably the
amount of DNA required for qualification was different among
studies. Table 4 shows that three studies required between 50 ng
and 1.25 mg of DNA to perform genotyping analyses (KIDD
(qualification 100%), PAND (96.32%) and BRCD/PROD
(100%)) whereas INTD required samples with more than 10 mg
of DNA at a concentration $10 ng/ml, thus explaining the lower
qualification rate (84.02%) due to samples with low concentration/
yield. Aside from amount of DNA, other reasons for non-
qualification were gender discordance between sample annotation
and quality control assessment (between 0.42 and 0.97%) and low
SNP call rate (between 0.53 and 2.76%), depending upon studies
(Table 5). Thus, the main reason for non-qualification was
insufficient DNA yield and concentration.
Discussion
This study is, to our knowledge, the largest to date to evaluate
the sources of pre-analytical variations in DNA extracted from
blood samples for Genome Wide Analysis Studies. So far, there
has been no systematic assessment of these sources of variations.
Early studies discussing these variations have merely listed steps in
the procedure and factors that may affect DNA yield without
quantifying their respective impact [9]. In contrast, recent studies
have evaluated the use for GWAS of DNA of different source/
quality to compare their suitability, without discussing the impact
of sources of variations [10]. Our study is unique in its relatively
homogenous study design and infrastructure context (the EPIC
cohort and the IARC DNA extraction facility), in which it is
expected that sources of variations would be relatively well
controlled. In particular, the EPIC centers included in this study
have adopted standardized protocols for blood collection by
venipuncture, processing, aliquoting and shipment to IARC.
Furthermore, DNA extractions at IARC were processed in a single
Table 4. Inclusion criteria for genotyping projects.
Criteria Number of samples excluded
Project
Number of
samples Quantity Concentration
Insufficient
yield
Low
concentration
% of samples
failed
% of samples
qualified for
genotyping
Kidney (KIDD) 258 50 ng 50 ng/ml 0 0 0 100
PanScan (PAND) 489 1250 ng 25 ng/ul n/a 18 3.68 96.32
BPC3 (BRCD+PROD) 5684 250 ng 50 ng/ml 0 0 0 100
Interact (INTD)d 20794 10 mg 50 ng/ul 433 2889 15.98 84.02
dSamples not having the required amount of DNA (with less than 10 mg of DNA) were sent to the laboratory.
doi:10.1371/journal.pone.0039821.t004
Figure 1. Distribution of yield (mg) for DNA samples extracted with 2 aliquots of buffy coat. Representation of DNA yield for DNA
extractions performed from 2 buffy coat aliquots. Boxes extend from 25th to 75th percentiles and are divided by a solid line representing the median
of each center. Whiskers extend from lower to upper adjacent values as defined by Tukey. Outliers are denoted by a dot.
doi:10.1371/journal.pone.0039821.g001
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pipe-line with the majority being processed using automated DNA
extraction technology.
The large numbers of samples compiled in this study has
allowed us to identify several factors that significantly impact on
the DNA yield. Importantly, the largest variation in DNA yield
was observed between centers, accounting up to 16.9% of the
explained variation in DNA yield. The reasons for these inter-
center variations may reside in multiple components of the
laboratory setting, including room temperature, transport condi-
tions between the place of blood taking and the processing
laboratory, the performance of the centrifuge and, importantly,
the skills of the laboratory staff to identify buffy coats and
effectively recover them in an adequate manner. Although
considered as a simple procedure, buffy coats are difficult to
identify and recover manually in a reproducible way. The buffy
coat interface can be fuzzy and sometimes barely visible. Their size
and distribution in the centrifuge tube may also be affected by
blood viscosity. Furthermore, the buffy coat layer is unstable and
might be perturbed by brisk manipulation of the tube after
centrifugation.
After adjustment for main variables (center, age, gender, BMI,
tobacco consumption, number of straws, extraction method and
quantification method), three individual factors had a measurable
and significant effect: gender, age and body mass index. The
difference in DNA yield between women and men is small (the
yield in women is, on average, 1.4 mg higher than in males) and
might be related to variation in lymphocyte, platelets and
neutrophils counts (all higher in females than in males) [11].
Similarly, the decrease in DNA yields in relation to age might be
caused by decreased number of white cells in the peripheral
circulation with age. The decrease in yield might also be
influenced by differences in the composition of the white blood
cells (WBC) pool that may modify the appearance and thus the
retrieval, of the buffy coat. Many years ago, Erkeller-Yuksel and
collaborators have studied the age-related changes in human
blood lymphocytes subpopulations [12]. They showed that the
decrease in lymphocytes counts with age is progressive in all 5-
years age groups and that there is no significant acceleration in
older subjects. Richardson and collaborators reported similar
findings in their study on the evaluation of the effects of blood
storage at 4uC on the DNA yield and quality [13]. In this study the
main determinant on DNA yield was the age of the participant in
the study, with older persons having a lower DNA yield.
With BMI, using a BMI of 25 or under as reference, we found a
progressive increase in DNA yield independently of age, the largest
increment being detected in highly obese subjects with a BMI
$35 Kg/M2. This increase is likely to be due to an increased
number of inflammatory, reactive white blood cells in relation to
obesity, a phenomenon which is well documented [14].
DNA yield was affected by tobacco consumption. The DNA
recovered from buffy coat was increased by 15.8% in smokers
compared to non-smokers. An increase in WBC counts has been
documented in smokers, especially leucocytes or lymphocytes
subpopulations among smokers [15]. Conversely, smoking cessa-
tion has been shown to result into decreased WBC counts to levels
comparable to those of never smokers [16,17]. The increase in
WBC counts and subsequent DNA yield in smokers might be
caused by chronic inflammation induced by tobacco and is
consistent with the hypothesis that blood-derived DNA might
represent a source of biomarkers of molecular changes associated
with smoking.
We also found that DNA yield varied significantly according to
the cancer case or control status of the subjects. Incident cancer
cases had, on average, a greater yield of DNA. This difference was
relatively small as compared to the average DNA yield, precluding
the use of increased DNA yield as an indicator of cancer risk at the
individual level (about 4%). Nevertheless, this increase was
strongly statistically significant even after adjusting for all other
factors including those that might predict higher cancer risk (age,
BMI, tobacco). This increase in DNA yield in subjects who will
develop cancer during follow-up (mean follow-up time: 5.2 years)
might be due to the expansion of pools of WBC involved in
cancer-specific immune response, and/or to an increase in
inflammatory cells; whereas a contribution of circulating cells
originating from an undiagnosed, early lesion can also not be
excluded. In breast cancer patients, for example, it has been shown
that circulating tumor cell (CTC) assessment could be an indicator
of disease progression [18]. Interestingly, there was no significant
difference in DNA yield for subjects with prevalent cancer (that is,
subjects who had a diagnosis of cancer before recruitment into
EPIC). This observation suggests that DNA yields return to basal
levels in apparently disease-free cancer survivors.
The other sources of DNA yield variations identified in this
study are of a technical nature. Some of these variations can be
associated with pre-analytical DNA processing. Interestingly, the
times elapsed between blood draw and refrigeration and between
refrigeration and centrifugation had an impact on DNA yield,
albeit these effects were relatively small. It should be considered
that, in the EPIC protocol, these time periods were carefully
monitored and controlled in order to minimize variation. Larger
variations might be expected in studies where sample collections
are assembled from centers that do not use protocols agreed upon
Table 5. Qualification for different genotyping method.
Project
Genotyping
method Platform/technology Site
Number of
samples selected
for genotyping
% of samples
genotyped
that passed
Failed
genotyping Criteria
Kidney (KIDD) GWAS Illumina Infinium 610 K CNG, Evry, France 258 100.00 0
PanScan
(PAND)
GWAS Illumina Infinium II
Human 550 K Bead
NCI, Bethesda,
USA
471 96.82 15 ,98% call rate
(n = 13, 2.76%),
gender (n = 2, 0.42%)
BPC3
(BRCD+PROD)
GWAS Illumina Golden Gate ICL, London, UK 5684 99.47 30 ,75% call rate
(n = 30, 0.53%)
Interact (INTD) I-plex Sequenom MRC, Cambridge,
UK
17472 98.48 265 ,75% call rate
(n = 96, 0.55%),
gender (n = 169, 0.97%)
doi:10.1371/journal.pone.0039821.t005
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by all centers at the onset of the study. Another, minor source of
variation was observed in relation to the two automated DNA
extractors that were used throughout these studies, indicating that
they have slightly different performances. The yield with the
automated DNA extractors was higher than for the samples
extracted manually using Gentra Puregene columns (Qiagen,
Hilden, Germany). However the number of DNA samples that
were manually extracted represented less than 1% of the total
(415/47,161). Manual methods were used only as a backup when
automated extractors were undergoing maintenance or repair.
In the present series of samples, most extractions were
performed using 2 straws of buffy coat (74.8%) while a minority
was performed using a single straw. Strikingly, the amount of
DNA obtained from 2 straws was systematically less than double
the amount obtained from one straw. The difference between one
and two straws was, on average, 79.13%. This apparent
inconsistency might be explained by inequality between the two
straws in terms of the quantity of buffy coat material. Whereas the
standard EPIC protocol included the collection of 4 identical
straws of buffy coat (2 to be stored at the collection center and 2 in
the central EPIC biobank at IARC), variations in the filling of the
straws might have occurred in particular when buffy coats were in
short supply. Extraction from a single straw was often performed
from the ‘‘most filled of two’’ available straws as judged by eye by
the technicians responsible for sample recovery in the liquid
nitrogen tanks.
We also detected variations in relation with to the method used
for DNA quantification. Overall, Picogreen detection tended to
provide higher yields than Nanodrop, an unexpected observation
since others have reported that Nanodrop tended to overestimate
DNA yields due to insufficient discrimination between double
stranded DNA and single stranded nucleic acids [19]. Further-
more, the difference we observed was essentially for samples with
low DNA yields, since when using 2 straws for extractions, the
values obtained with both quantitation methods were similar
(75.4 mg with Picogreen versus 77.6 mg with Nanodrop). Further
studies are needed to fully assess the extent of the differences
between Picogreen and Nanodrop quantitation over a wide range
of DNA concentrations.
The largest sources of variation were the degree of sample
haemolysis and the center from which the sample originated. The
scoring of haemolysis was based on a simple visual, qualitative
assessment. Furthermore, data are missing for about half of the
samples. Given that heavy haemolysis appears to cause a decrease
in DNA yield of about 13.8%, this factor may be a non-negligible
cause of variations in DNA yield and should be taken into account
in annotating sample quality in biobank databases.
Genotyping data indicated that the vast majority of samples
performed adequately in different types of SNP assays (pass rate
between 84.02% and 100%). There are two main reasons for
failures, samples failing to be included in genotyping because of
DNA quantity and samples excluded from genotyping results due
to SNP call rate or gender error. The first reason for failure was
insufficient DNA amount or concentration as measured by the
laboratory which performed the assay. This factor had a
particularly important impact for the INTD study (n= 20.794),
being responsible for 15.98% of the failures in this particular study.
In this respect, INTD was different from the three other studies for
which genotyping data are currently available, since the laboratory
performing the genome-wide INTD study required 10 mg of DNA
and a concentration $10 ng/ml, a much higher level than other
studies such as PAND or KIDD which required only up to 1.25 mg
of DNA. Moreover for KIDD, PAND and BRCD/PROD,
samples not having the required amount of DNA were not sent
by the IARC BRC to the laboratory whereas for INTD, all
samples including those with less than 10 mg of DNA were sent to
the laboratory. This particularity for INTD explains the lower
percentage of samples qualified for genotyping (84.02% for INTD
compared to 100% for KIDD and BRCD+PROD, and 96.32%
for PAND).
Once qualified, only between 0.53% and 2.76% of samples
failed the genotyping procedure. The second reason for failure is
due to SNP call rate or gender discordance. It is important to note
that there is very little information on the extent of inter-
laboratory variations in GWAS studies, most studies on the
repeatability being focused on statistical considerations for SNP
calling. Our results emphasize the fact that other factors, including
particular DNA quality and methods for determining which
samples qualify for GWAS analysis, may have a significant impact
as sources of possible variations.
In summary, this study uses a very large set of DNA extraction
data from a single cohort study (EPIC) to identify several
anthropometric, epidemiological and technical factors that influ-
ence the overall DNA yield using an automated DNA extraction
procedure. Although the vast majority of the samples met the
qualification criteria for genotyping studies in different laboratory
contexts, the results presented here will provide a strong basis for
further recommendation in order to improve blood collection and
processing protocols in large-scale genetic studies. In particular, it
will be essential to develop simple and cheap tests to assess the
quality of buffy coat recovery prior to storage and DNA extraction
or where possible to use automated methods for extraction of
DNA from whole blood. Another option could be to investigate
the benefit of using stand alone automated devices for the
identification and transfer of buffy coats. Finally, our results
highlight the importance of adequate training and quality control
procedures for minimizing inter-center variations as well as
temporal variations within each center.
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